Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.68 |
| ▸ | MAOB | P27338 | 5/20 | 0.68 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344560 | 0.84 | MAOA (0.72) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL13930053 | 0.84 | MAOA (0.72) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL2561325 | 0.84 | MAOA (0.72) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL23125436 | 0.81 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL14527007 | 0.81 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL5443706 | 0.81 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL23125472 | 0.81 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL4316968 | 0.81 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL5447555 | 0.80 | MAOA (0.97) | MAOAMAOBACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL5439146 | 0.80 | MAOA (0.97) | MAOAMAOBACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131535-A1 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | TEVA PHARMACEUTICALS INDUSTRIES, LTD. | 2009-05-21 | — | — | US | disclosed |
| EP-1490324-A4 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | TEVA PHARMA (IL) | 2007-10-10 | — | — | EP | disclosed |
| EP-1490324-A2 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-29 | — | — | EP | disclosed |
| US-20040010038-A1 | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-01-15 | — | — | US | disclosed |
| WO-2003072055-A2 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010038-A1 | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors | MAOA, MAOB, AOC3 | MAOA 1/4885MAOB 2/4885ACHE 87/4885 |
| US-20090131535-A1 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | MAOA, MAOB, AOC3 | MAOA 1/4885MAOB 2/4885ACHE 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.